Journal of Applied Physiology, Vol 74, Issue 4 1492-1498, Copyright © 1993 by American Physiological Society

ARTICLES

Inhibition of antigen-induced airway and cutaneous responses by heparin: a pharmacodynamic study

T. Ahmed, T. Syriste, J. Lucio, W. Abraham, M. Robinson and J. D'Brot
Division of Pulmonary Disease, University of Miami School of Medicine, Mount Sinai Medical Center, Miami Beach, Florida 33140.

We have previously shown that heparin attenuates the acute bronchoconstrictor response and immediate cutaneous reaction (ICR) to antigen in allergic sheep. In the present investigation, we studied the pharmacodynamics of the antiallergic action of heparin. Specific lung resistance (sRL) was measured in eight sheep, allergic to Ascaris suum antigen, before and 5 min after inhalation challenge with the antigen. On different experiment days, antigen challenge was repeated after pretreatment with 1) aerosol heparin (1,000 U/kg) administered < or = 20 min, 6 h, 12 h, and 24 h and 2) intravenous heparin (1,000 U/kg) administered < or = 20 min, 1 h, 6 h, and 12 h before antigen challenge. sRL increased by 374 +/- 116% (SE) above baseline with antigen alone. Both aerosol and intravenous heparin attenuated the antigen effects on sRL in a time-dependent fashion. Prolonging the lag time between pretreatment and antigen challenge decreased the inhibitory effect of aerosol heparin; delta sRL was 31 +/- 29, 99 +/- 38, 142 +/- 40, and 306 +/- 60% for < or = 20-min, 6-h, 12-h, and 24-h pretreatment protocols, respectively. In contrast, prolonging the lag time increased the inhibitory effect of intravenous heparin: delta sRL was 246 +/- 64, 66 +/- 26, and 76 +/- 32% for < or = 20 min, 1 h, and 6 h, respectively. In seven additional sheep pretreatment with intravenous heparin (1,000 U/kg) attenuated the ICR also in a time-dependent manner; the inhibitory effect of heparin on ICR to antigen was enhanced 60% by increasing the heparin pretreatment interval from 20 to 60 min.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S. He, A. Aslam, M. D. A. Gaca, Y. He, M. G. Buckley, M. D. Hollenberg, and A. F. Walls Inhibitors of Tryptase as Mast Cell-Stabilizing Agents in the Human Airways: Effects of Tryptase and Other Agonists of Proteinase-Activated Receptor 2 on Histamine Release J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 119 - 126. [Abstract] [Full Text]

				T. AHMED, B. J. GONZALEZ, and I. DANTA Prevention of Exercise-induced Bronchoconstriction by Inhaled Low-molecular-weight Heparin Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 576 - 581. [Abstract] [Full Text]

				S. He, M. D. A. Gaça, and A. F. Walls A Role for Tryptase in the Activation of Human Mast Cells: Modulation of Histamine Release by Tryptase and Inhibitors of Tryptase J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 289 - 297. [Abstract] [Full Text]

				J. F. MOLINARI, C. CAMPO, S. SHAKIR, and T. AHMED Inhibition of Antigen-induced Airway Hyperresponsiveness by Ultralow Molecular-weight Heparin Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 887 - 893. [Abstract] [Full Text] [PDF]

				J. Martinez-Salas, R. Mendelssohn, W. M. Abraham, B. Hsiao, and T. Ahmed Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence J Appl Physiol, January 1, 1998; 84(1): 222 - 228. [Abstract] [Full Text] [PDF]

				T. Ahmed, J. Garrigo, and I. Danta Preventing Bronchoconstriction in Exercise-Induced Asthma with Inhaled Heparin N. Engl. J. Med., July 8, 1993; 329(2): 90 - 95. [Abstract] [Full Text]